Sollpura's Future After No Vote From Panel Might Include More Trials, Adult Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Gastrointestinal Drugs Advisory Committee says in lopsided votes that Lilly's exocrine pancreatic insufficiency drug candidate Sollpura (liprotamase) lacks proof of efficacy.